vTv Therapeutics Inc.
VTVTNasdaq
$32.88
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↑ +93.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$36.8M
Net Income (TTM)
$2.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-8.3%
Net Margin
6.1%
ROE
2.5%
ROIC
—
Debt / Equity
—
Net Cash
$98.1M
Return 1Y
+103.5%
Company profile
vTv Therapeutics focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion.
- CEO
- Paul J. Sekhri
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- North Carolina
- Website
- vtvtherapeutics.com
Earnings
VTVT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$36.8M—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | $4.0M | $2.0M | $0.00 | $1.0M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$11.9M | -$21.7M | -$22.5M | -$25.5M | -$24.2M | -$32.8M |
| Net income | -$8.5M | -$13.0M | -$19.2M | -$20.3M | -$18.5M | -$27.0M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$18.0M | -$19.3M | -$16.0M | -$19.1M | -$25.3M | -$25.3M |
| Free cash flow | -$18.0M | -$19.3M | -$16.0M | -$19.1M | -$25.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -184.8% | -540.9% | -1116.9% | — | -2377.6% | — |
| Net margin | -132.5% | -324.3% | -949.7% | — | -1815.3% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $17,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $36.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.2M | -$6.5M | -$4.9M | -$6.5M | -$7.7M | -$10.7M | -$7.9M | $23.3M |
| Net income | -$5.2M | -$4.8M | -$3.6M | -$5.1M | -$6.0M | -$8.7M | -$7.1M | $24.1M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$6.7M | -$6.4M | -$4.8M | -$5.7M | -$5.1M | -$5.2M | -$9.3M | $9.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -28776.5% | — | — | — | — | 63.1% |
| Net margin | — | — | -21376.5% | — | — | — | — | 65.5% |
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-22 | AKKARAJU SRINIVAS | Award | 106,000 | $15.27 | $1.6M | filing |
| 2025-09-22 | AKKARAJU SRINIVAS | Award | 106,000 | $15.27 | $1.6M | filing |
| 2025-09-03 | BAKER BROS. ADVISORS LP | Award | 4,308 | — | — | filing |
| 2025-09-03 | BAKER BROS. ADVISORS LP | Award | 46,692 | — | — | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.